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OBJECTIVE
To evaluate the safety and efficacy of methazolamide as a potential therapy for
type 2 diabetes.
RESEARCH DESIGN AND METHODS
This double-blind, placebo-controlled study randomized 76 patients to oral meth-
azolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point
for methazolamide treatment was a placebo-corrected reduction in HbA1c from
baseline after 24 weeks (DHbA1c).
RESULTS
Mean6 SD baseline HbA1c was 7.16 0.7% (546 5 mmol/mol; n5 37) and 7.46
0.6% (57 6 5 mmol/mol; n 5 39) in the methazolamide and placebo groups,
respectively. Methazolamide treatment was associated with a DHbA1c of
–0.39% (95% CI –0.82, 0.04; P < 0.05) (–4.3 mmol/mol [–9.0, 0.4]), an increase in
the proportion of patients achieving HbA1c £6.5% (48 mmol/mol) from 8 to 33%, a
rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in
metformin-cotreated patients.
CONCLUSIONS
Methazolamide is the archetype for a new intervention in type 2 diabetes with
clinical benefits beyond glucose control.
Methazolamide is a carbonic anhydrase (CA) inhibitor that was approved by the U.S.
Food and Drug Administration in 1959 as a treatment for glaucoma. The safety
profile of methazolamide has been well characterized through its long history of
clinical use at doses from 50 to 100 mg b.i.d. or t.i.d. The most common side effect
reported for methazolamide is reversible, dose-dependent, metabolic acidosis,
which is a consequence of CA inhibition (1).
The potential antidiabetes activity of methazolamide was identified using a Gene
Expression Signature screening technology (2). The glucose-lowering efficacy of
methazolamide was established in studies using db/db and DIO mice, where meth-
azolamide was also found to have more-than-additive efficacy in combination with
metformin. Methazolamide was ineffective in insulin-deficient streptozotocin-
treated rats but significantly enhanced the glucose-lowering effect of exogenous
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insulin administered to these animals
(3). These data suggest that methazol-
amide is a novel insulin sensitizer that is
complementary to metformin. Ongoing
mechanistic studies have shown that
methazolamide exerts its metabolic ef-
fects by a mitochondrial mechanism dis-
tinct from CA inhibition.
RESEARCH DESIGN AND METHODS
This was a randomized, double-blind,
placebo-controlled, proof-of-concept
study conducted at three sites in Aus-
tralia between 2010 and 2012. The pro-
tocol and amendments were approved
by independent ethics committees and
institutional review boards. The study
was implemented according to Good
Clinical Practice and the Declaration of
Helsinki. All study patients gave written
informed consent prior to screening.
Eligible patients included men and
women between the age of 18 and
75 years with type 2 diabetes. Key inclu-
sion criteria were a hemoglobin A1c
(HbA1c) at screening of 6.5–8.5% (48–69
mmol/mol), body weight .50 kg, and a
BMI #40 kg/m2. The study included pa-
tients who were not treated with any
diabetes medication (Non-MET) and pa-
tients who had been treated with met-
formin for at least 3 months and had a
stable metformin dose for at least 8
weeks prior to study entry (MET). Met-
formin doses were not altered through-
out the study (Supplementary Fig. 1).
Patients were randomized in a 1:1 ra-
tio to receive either methazolamide (40
mg b.i.d.) or matching placebo for 24
weeks. Blood samples for biochemistry,
venous blood gases, fasting blood glu-
cose, and insulin were taken at screening,
day 0, and weeks 1, 2, 4, 8, 12, 18, and 24.
HbA1c measurements, hematology, lipid
profile, and urinalysis were conducted
at screening, day 0, and weeks 12 and
24. Patients were consulted by telephone
at weeks 3, 10, 15, and 21, and a tele-
phone follow-up was conducted 30 days
after study completion.
The primary efficacy end point was
the change in HbA1c from baseline to
24 weeks (DHbA1c) in the pooled (Non-
MET1MET) methazolamide group com-
pared with the pooled placebo group
(Non-MET1MET). The primary safety
end point was the incidence of meta-
bolic acidosis (based on venous blood
gas parameters), defined as one of the
following: pH#7.25 in repeated venous
blood gas analysis and confirmed by ar-
terial blood gas analysis, bicarbonate
,20 mmol/L, or base excess below –5.
The studywas powered to demonstrate
superiority of the pooled (Non-MET1
MET) methazolamide group over the
pooled placebo group for the primary effi-
cacy end point. There were insufficient
patient numbers for comprehensive sta-
tistical comparisons between the Non-
MET andMET groups. Statistical analyses
were performed in accordance with
ICH E9 guidelines using SAS, version 9.2
(SAS Institute, Cary, NC). Changes in
HbA1c, fasting blood glucose, serum ala-
nine aminotransferase (ALT), microalbu-
min, and blood pressure were evaluated
using repeated-measures ANCOVA with
missing data imputed using a last obser-
vation carried forward strategy. Treat-
ment group differences were estimated
using least squares means and 95% CIs
based on the mean square error from
ANCOVA using a one-sided significance
level (P, 0.05).
RESULTS
A total of 132 patients were screened, and
76were enrolled in the study. Baseline de-
mographic parameters and HbA1c were
well matched between groups (Table 1
and Supplementary Table 1). Ten patients
(13%) discontinued the study: 5 placebo-
treated and 5 methazolamide-treated.
The clinical study achieved its protocol-
specified primary efficacy end point,
demonstrating a statistically significant
reduction in HbA1c from baseline to
week 24 in methazolamide-treated pa-
tients relative to placebo (Table 1).
Greater reductions in HbA1c were ob-
served in patients with higher baseline
HbA1c, and a statistically significant re-
gression was noted between DHbA1c and
baseline HbA1c values in methazolamide-
treated patients (Supplementary Fig. 2).
The proportion of patients with HbA1c
#6.5% (48 mmol/mol) increased from
day 0 to week 24 in the methazolamide
group but was unchanged in the placebo
group (Table 1).
Methazolamide treatment caused a
significant reduction in serum ALT from
baseline to week 24 compared with
placebo (Table 1). The ALT reduction
occurred as early as week 1 and contin-
ued for the duration of the study (Supple-
mentary Fig. 2). There were no significant
alterations to g-glutamyltransferase
(mean6 SD for placebo 1.66 13.4 units/L,
methazolamide –1.8 6 10.4 units/L) or
other liver markers.
Methazolamide-treated patients also
had reduced urinary microalbumin com-
pared with placebo at week 24 owing
exclusively to microalbumin reductions
in MET patients. There were no signifi-
cant changes in creatinine or urea, and
the incidence of abnormal renal func-
tion (defined as .10% reduction in
eGFR) was similar for methazolamide
(30%) and placebo (36%).
Changes in bodyweightwere not differ-
ent between the pooled methazolamide
and pooled placebo groups; however, in
the MET group, methazolamide-treated
patients lost more body weight (–2.2 6
3.6 kg, n 5 21) than placebo-treated pa-
tients (–0.36 1.7 kg, n 5 18) at week 24
(P 5 0.04, ANOVA with two-sided t test).
In the Non-MET group, methazolamide-
and placebo-treated patients lost similar
amounts of body weight (Supplementary
Fig. 3).
There were no incidences of hypogly-
cemia or hypotension and no significant
effects of methazolamide on fasting
blood glucose; homeostasis model as-
sessment of insulin resistance; fasting
insulin; HDL, LDL, or total cholesterol;
triglycerides; blood pressure; venous
pCO2 or pO2; electrocardiograms; safety
laboratory measures; or electrolyte dis-
turbances. Metabolic acidosis was diag-
nosed in seven methazolamide-treated
patients (five MET, two Non-MET) and
no placebo patients. None of the pa-
tients with acidosis showed any clini-
cally significant symptoms, and all
remained on study (Supplementary Ta-
ble 2). A greater proportion of patients
in the methazolamide treatment arm
(26 of 37 [70%]) reported adverse
events (primarily respiratory tract infec-
tions and nausea) compared with pla-
cebo (23 of 39 [59%]). None of the
adverse events were considered to be
definitely related to study medication
(Supplementary Table 3).
CONCLUSIONS
Methazolamide is the archetype for a po-
tential new class of type 2 diabetes ther-
apy. In addition to reducing HbA1c,
methazolamide provided unexpected ad-
ditional clinical outcomes, including a
rapid and persistent reduction in ALT
and weight loss in metformin-cotreated
patients. Type 2 diabetes is a risk factor
for the development of liver diseases (4,5),
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and studies are ongoing to evaluatemeth-
azolamide liver effects on liver pathology.
The current studywas limited by a small
sample size (requiring pooling of MET and
Non-METpatients) and lowbaselineHbA1c
levels, which reflected the available
patient demographic at the study sites. A
larger study of methazolamide in patients
with higher baseline HbA1c levels is
expected to demonstrate greater HbA1c
reductions and enable a prospective eval-
uation of methazolamide effects on body
weight and liver function. Lower meth-
azolamide dosesmay reduce the potential
incidence of metabolic acidosis, and the
present data encourage the development
of novel, non–CA-inhibiting methazol-
amide analogs as diabetes therapies.
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Table 1—Baseline demographics and changes in key parameters upon methazolamide treatment
Parameter Placebo Methazolamide
Baseline*
Patients, n 39 37
Male, n (%) 22 (56) 28 (76)
Age (years) 63 6 9 63 6 9
Race, % white 97 89
Taking metformin, n (%) 19 (49) 22 (59)
Concurrent cardiovascular condition, n (%)† 28 (72) 27 (73)
Body weight (kg) 90.4 6 16.1 92.6 6 14.3
BMI (kg/m2) 30.9 6 4.2 31.8 6 4.9
Fasting blood glucose (mmol/L) 8.6 6 2.2 8.1 6 1.5
HbA1c [% (mmol/mol)] 7.4 6 0.6 (57 6 5) 7.1 6 0.7 (54 6 5)
Microalbumin (mg/mL) 68.2 6 211.1 29.7 6 100.7
ALT (units/L) 33.9 6 16.1 31.5 6 15.3
GGT (units/L) 42.6 6 37.0 38.4 6 29.1
Diastolic blood pressure (mmHg) 83.7 6 9.1 81.6 6 11.1
Systolic blood pressure (mmHg) 136.2 6 15.2 137.3 6 14.4
Placebo Methazolamide Treatment effect§







Patients with HbA1c #6.5% (#48 mmol/mol), n (%)
Day 0 5 (13) 3 (8)
Week 24 5 (14) 11 (33)¶
DFasting blood glucose from baseline to week 24 (mmol/L)‡ 0.25 (–0.32, 0.82) 0.01 (–0.54, 0.55) 20.24 (–1.00, 0.52);
P 5 0.2597
DMicroalbumin from baseline to week 24 (mg/mL)‡ 19.4 (–25.4, 64.3) 237.4 (–86.0, 11.3) 256.8 (–122.6, 9.0);
P 5 0.0446
DALT from baseline to week 24 (units/L)‡ 20.1 (–3.0, 2.9) 210.2 (–13.3, –7.0) 210.1 (–14.0, –6.1);
P , 0.0001
Data are means 6 SD or least squares means (95% CI) unless otherwise indicated. GGT, g-glutamyltransferase. *Safety population included all
patients who received at least one dose of study medication. †Percentage of all patients with at least one of the following: hypertension,
hypercholesterolemia, and/or hyperlipidemia; patients often had more than one. ‡The intent-to-treat population included all randomized patients
who received at least one dose of study medication and who had at least one valid observation for an efficacy variable while on study medication.
§Methazolamide change – placebo change. ¶P , 0.05 by post hoc analysis using a two-sided t test.
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